Esophageal Cancer
Conditions
Keywords
Esophageal Cancer, Adaptive Radiation Therapy
Brief summary
The purpose of this study is to evaluate the benefit of adaptive radiation therapy (adaptive radiation therapy, ART) for esophageal cancer, using dose tracking technique with online images and deformable registration.
Detailed description
The aim of study is to evaluate the benefit of adaptive radiation therapy(ART) for esophageal cancer. 80 patients with locally advanced esophageal cancer will be treated with 3D-CRT(three dimensional conformal radiotherapy, 3D-CRT)/IMRT(intensity modulated radiotherapy, IMRT), dividing to experimental group and control group (40 patients each). All patients are kVCT(kilo-voltage computed tomography, kVCT) scanned weekly(the fifth fraction in a week) and CBCT (cone beam computed tomography, CBCT) scanned per fraction before treatment. Irradiated dose distribution of each patient is calculated using the CBCT images corrected with validated modelling and accumulate the volumetric dose for all PTV(planning target volume,PTV) and OARs(organs at risk, OAR) using deformable registration algorithm. For the experimental group, replan the treatment when the target volume is not covered by the prescribed dose or OARs is overdose beyond the action level to achieve an optimal dose distribution. Conversely, no action is taken in the control group and the original plan will be used for the full treatment course. Dosimetric parameters (such as the ratio of target coverage, the mean dose of OARs, etc) ,treatment toxicities (such as radiation pneumonitis and esophagitis), PFS（Progress Free Survival,PFS）and OS（Overall Survival, OS）of the two groups will be analyzed and compared in the study.
Interventions
RADIATIONDose adaptation
Replanning the treatment to adapt the change of PTV and movement of OARs to achieve an optimal dose distribution using online CBCT images.
Sponsors
Sun Yat-sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosed with locally advanced esophageal cancer * ECOG(Eastern Cooperative Oncology Group, ECOG) physical status score：0-2 * Charlson complications index score≤4 * First second forced expiratory volume ≥1 liter * Patients and their families agreed and signed the informed consent
Exclusion criteria
* Previous treatment with other malignant tumor * Had anti-tumor treatment, including (chemotherapy, radiotherapy, surgery) * Any taboo disease or condition of radiotherapy and chemotherapy * With malignant pleural effusion and pericardial effusion * Participated to other clinical test within 30 days before this experiment * With uncontrolled seizures or loss of mental self-control * Drug takers, chronic alcoholism, and HIV/AIDS patients * Has a history of severe allergic or specific physique * Researchers think that is unfavorable to the test
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Toxicity of treatment | One year | Evaluating the treatment toxicity weekly during treatment course and at the time of one year after treatment according to the NCI CTCAE 4.0 (The National Cancer Institute Common Terminology Criteria for Adverse Events,NCI-CTCAE, Version 4.0). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progress Free Survival(PFS） | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months. | the length of time during and after the treatment of a disease |
| Overall Survival（OS） | 2 years | The survival time from the start of treatment to death or the time of the last follow-up of this study. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Dosimetric Parameters | Six weeks | Accumulated dose distribution of the full treatment course. |
Countries
China
Contacts
Primary ContactLiu Hui, PHD.
Backup ContactQiu Bo, PHD.
Outcome results
None listed